Disitamab (Anti-ERBB2 / HER2 / CD340) is a humanized monoclonal antibody targeting HER2. It can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin. The ADC also known by its trade name Aidixi, which used in the treatment of various solid tumors. It combines a monoclonal antibody Disitamab targeting the HER2 receptor with a cytotoxic agent called monomethyl auristatin E (MMAE) by a linker. It has antitumor and antineoplastic activities. MW :144.16 KD. This product is for research use only.
Product Details |
Species Reactivity | Human |
---|
Host/Isotype | Human IgG1 |
---|
Class | Monoclonal |
---|
Type | Recombinant Antibody |
---|
Immunogen | Human ERBB2 / HER2 |
---|
Clone | Disitamab biosimilar |
---|
Conjugate | Unconjugated |
---|
Purity | ≥ 99% |
---|
Molecular Weight | 144.16 KD |
---|
Protein Concentration | 1mg/ml |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | 100mM Pro-Ac, 20mM Arg-Ac, pH 5.0 |